VNDA at a glance
Vanda Pharmaceuticals Inc. (VNDA, SEC CIK 1347178) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as June 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Vanda Pharmaceuticals Inc. (VNDA) reported revenue of $216.1 million (up 8.7% from FY2024) and a net loss of $220.5 million. Diluted EPS was -$3.74.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Vanda Pharmaceuticals Inc. (VNDA) shares worth $188.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Moran Kevin Patrick on March 2, 2026 of 42,442 shares at $8.27 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $216.1M
- +8.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $188.1M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $50.5M, down 4% YoY from $52.6M
- Fanapt sales $36.0M, up 23% YoY; strongest product performance
- HETLIOZ sales $5.6M, down 66% YoY; weakest product performance
- NEREUS sales $1.0M following May 2026 U.S. launch
- Near-term outlook: BYSANTI launch expected second half of 2026; NEREUS demand and returns constrain revenue
Risk Factors
- New tariff risk triggered by April 2, 2026 proclamation imposing 100% duties on certain pharmaceutical and API imports
- Manufacturing dependence on foreign third parties could increase costs and reduce margins if exemptions do not apply
- Regulatory replacement risk from FDA approval requirements for chemistry, manufacturing and controls changes
- Supply-chain disruption risk from limited alternative manufacturers and lengthy supplier replacement processes
- Carried-forward risk factors otherwise unchanged from the December 31, 2025 Annual Report
AI summary of the VNDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Quarterly results covered period ended June 30, 2026
- Press release furnished as Exhibit 99.1; key financial figures require review of the exhibit
Item EX-99.1: Item EX-99.1
- Q2 revenue $50.5M, down 4%; Fanapt sales rose 23% to $36.0M, offset by HETLIOZ decline
- Net loss widened to $62.5M, or $1.04 per share, from $27.2M as R&D and launch spending increased
Item 5.07: Submission of Matters to a Vote of Security Holders
- 80.7% quorum; 48,509,906 of 60,135,062 eligible shares represented
- Richard W. Dugan, Charles C. Duncan, Ph.D., and Anne Sempowski Ward elected through 2029
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results covered quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1; financial figures require review of the exhibit
AI summaries of VNDA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VNDA
Don't miss the next VNDA filing
- Alerts as it files. A push when VNDA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VNDA, by share count.
- Ask anything. An AI agent that reads every VNDA filing and answers with sources.
VNDA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McGuire Daniel Patrick | A | Jun 4, 2026 | 80,000 | - |
| Mitchell Stephen Ray | A | Jun 4, 2026 | 41,600 | - |
| Chrousos Phaedra | A | Jun 4, 2026 | 41,600 | - |
| DUGAN RICHARD W | A | Jun 4, 2026 | 41,600 | - |
| Ward Anne Sempowski | A | Jun 4, 2026 | 41,600 | - |
| Duncan Charles Cliff | A | Jun 4, 2026 | 41,600 | - |
| Honore Tage | A | Jun 4, 2026 | 41,600 | - |
| Mitchell Stephen Ray | G | May 18, 2026 | 25,836 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $198.8M | $216.1M |
| Operating Income | - | -$40.7M | -$151.2M |
| Net Income | $2.5M | -$18.9M | -$220.5M |
| Op. Margin | - | -20.5% | -70.0% |
| Net Margin | - | -9.5% | -102.0% |
| Balance Sheet | |||
| Total Assets | - | $656.2M | $488.9M |
| Equity | $544.9M | $538.5M | $327.2M |
| ROE | 0.5% | -3.5% | -67.4% |
| Per Share | |||
| EPS | $0.04 | $-0.33 | $-3.74 |
| Cash Flow | |||
| Operating CF | $12.8M | -$15.8M | -$109.4M |
| CapEx | - | $490K | $998K |
Source: XBRL data in Vanda Pharmaceuticals Inc. (VNDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VNDA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $188.1M |
| Q1 2026 | 24 | $192.8M |
| Q4 2025 | 23 | $216.5M |
| Q3 2025 | 24 | $139.7M |
| Q2 2025 | 26 | $135.5M |
| Q1 2025 | 22 | $81.6M |
| Q4 2024 | 18 | $70.8M |
| Q3 2024 | 17 | $50.9M |
- AQR Capital Management+1.89M (+118%)
- State Street Corp+500.8K (+17%)
- BlackRock+377.7K (+5%)
- Goldman Sachs Group+198.0K (+24%)
- Northern Trust+149.6K (+33%)
- Renaissance Technologies LLC−318.2K (-8%)
- Millennium Management−278.2K (-15%)
- Two Sigma Investments−49.1K (-4%)
- Dimensional Fund Advisors−44.2K (-2%)
- Invesco Ltd−14.5K (-8%)
- Prudential Financial+17.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VNDA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 19, 2026 | - | - | |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Apr 24, 2026 | - | - | - |
| 8-K | Apr 22, 2026 | - | Analysis | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VNDA SEC filings: frequently asked questions
Which institutions hold VNDA stock?
As of June 30, 2026, the largest Vanda Pharmaceuticals Inc. (VNDA) holders among the 13F filers tracked by SignalX were BlackRock ($46.8 million), State Street Corp ($21.5 million), AQR Capital Management ($21.4 million), Renaissance Technologies LLC ($21.1 million), Vanguard Capital Management LLC ($15.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VNDA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Vanda Pharmaceuticals Inc. (VNDA) reported revenue of $216.1 million (up 8.7% from FY2024) and a net loss of $220.5 million. Diluted EPS was -$3.74. The figures come from the XBRL data in the 10-K.
What did VNDA report in its latest 8-K?
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Quarterly results covered period ended June 30, 2026.
What are the latest VNDA SEC filings?
Vanda Pharmaceuticals Inc. (VNDA) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on June 8, 2026.
What is VNDA's SEC CIK number?
Vanda Pharmaceuticals Inc. (VNDA)'s SEC Central Index Key (CIK) is 1347178. EDGAR lists every VNDA filing under that number.
Ask anything about VNDA
The research agent reads VNDA's filings, financials, insider trades and 13F holders, then answers with sources.